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Abstract. Recent years witnessed an exciting increase in the number of clinical trials for neuromuscular disorders, in particular
for Duchenne Muscular Dystrophy and Spinal Muscle Atrophy. Given the high emotional impact of such developments for
devastating diseases with an urgent medical need, it is particularly important to justify human trials on the basis of robust
preclinical studies and to avoid a waste of hopes and of funds.
This review focuses the discussion on the quality in the conduct clinically-oriented preclinical assessments in rare neuromus-
cular disease models and on the importance in reporting of preclinical confirmatory studies. Accordingly, it invites scientists,
journal publishers and funding agencies to require quality standards to improve translatability of preclinical findings.
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INTRODUCTION
In the last few years, several publications, editorials
and commentaries have addressed the issue of trans-
parency and reproducibility in research. Robustness of
results is particularly important in research on animal
models with the aim of assessing the potential efficacy
of a treatment for patients, as such data may serve as
the basis for the hope of patients and for large and
expensive clinical trials. The low predictive power of
preclinical studies to translate into successful clinical
trials has caused frustration in the patients’ as well
as in the researchers’ communities [1–5]. The poor
translation of preclinical research is even more criti-
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cal in neuromuscular diseases because these disorders
are rare and have a limited number of patients: unsuc-
cessful trials will prevent patients from participating
in other trials and valuable resources and energy are
drained in these costly and complex multi-site clinical
trials. The rather poor predictability is often used to
incriminate animal models of disease in general as poor
predictors of drug efficacy. Surely, the response of ani-
mal models to drugs and treatments does not precisely
reflect the response in patients; however, animal mod-
els are and have been in the past very valuable tools
for understanding the complex and dynamic nature
of disease progression, and for developing therapeutic
concepts. Thus, testing potential treatment options in
animal models is certainly the most appropriate way to
select drug candidates and establish their potential clin-
ical benefit in humans. However, the lack of rigorous
and consistent design of the preclinical tests conducted
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with animal models can be one reason that contributes
to the failure in translation [6]. This review will discuss
a few, simple measures to minimize experimental vari-
ations and explore possibilities and obstacles linked to
this effort.
EXPLORATORY AND CONFIRMATORY
STUDIES
In the process of identifying new therapeutic targets
and developing potential treatments, many experimen-
tations aim at understanding a given physiological
pathway, generate hypotheses, investigate new possi-
bilities or methods. At a later time point, a confirmatory
study is necessary to provide compelling evidence that
the treatment is worth being tested in humans and that
it justifies the enormous financial and emotional effort
bound to a clinical trial [7]. Confirmatory preclinical
animal studies obviously need a high quality standard
and a careful study design, while these aspects are
less important in exploratory studies aimed at gen-
erating data for further development. Many of the
published preclinical studies are, however, conducted
as exploratory studies [8] but are then used to pro-
mote and sustain the conduct of a clinical trial. In
conclusion, while freedom and flexibility should be
granted in exploratory studies, the implementation of
rigor and quality in confirmatory preclinical animal
studies would be of great benefit for the planning of
successful clinical trials especially for rare neuromus-
cular diseases.
This however requires a wider awareness of the sci-
entific community and of journals’ editors in order
to optimize the efforts in this delicate translational
attempt.
QUALITY IN CONFIRMATORY
PRECLINICAL STUDIES FOR
NEUROMUSCULAR DISEASES
The problematic of bench research delivering effi-
cacy data that turn out not to show any efficacy in
patient studies is not new and was discussed thoroughly
in the communities of both rare and common diseases
[1, 5, 6, 9–11]. A general problem that makes it dif-
ficult to compare these studies and draw conclusions
is the incomplete reporting of experimental settings
or data generation. There is a common consensus on
the assumption that transparency, reproducibility and
finally also the predictive power of results can be
significantly increased by adopting standards in experi-
mental design like randomization and blinding, sample
size estimation and data handling [6, 12, 13].
In a detailed survey of preclinical efficacy/proof-
of-concept studies on the mdx mouse model, the
discrepancy between this common consensus and real-
ity becomes evident. The study, initiated and financed
by Parent Project Muscular Dystrophy USA, analysed
almost 200 papers published between 2000 and 2011
and recorded data reporting and drug study results.
Of all papers, randomization of mice in control and
treated groups was described in only 13% of the cases,
and parameters were assesses in a blinded way in only
7.4% of the papers (V. Malik and R. Willmann, per-
sonal communication). Only 2 papers reported sample
size calculations to justify the number of mice cho-
sen; in others, sample size was less than 8 mice per
group (40%) or was even not reported (14%). More
than 40% of the papers did not report mouse sex and
12.7% reported the use of mixed sexes, suggesting that
there is no consensus on detailed reporting of preclin-
ical data in the published papers. Finally, only about
16% reported the food regimen and brand used, despite
the fact that food composition can considerably vary
between suppliers and influences metabolism and effi-
cacy of pharmaceutical compounds. For instance, soy
protein has an impact on cellular responses and gene
expression [14], and 5 of the 6 diets compared in fact
used soy beans as protein source (R. Willmann, per-
sonal observation).
In addition to transparency in reporting, animal-
specific best practices that take account of bias related
to a specific animal model should be considered: this
issue was addressed for mouse models of Duchenne
Muscular Dystrophy [15] [5, 16] and also for other,
non neuromuscular diseases [10, 11]. Comparing rec-
ommendations suggested by the different authors
[15, 17–19] and guidelines adopted by single insti-
tutions (see for instance http://www.nih.gov/about/
reporting-preclinical-research.htm, based on [6]), it
seems that some general rules of transparency should
apply to all confirmatory preclinical studies, indepen-
dently of the disease addressed. These are summarized
in Table 1 and help structuring the confirmatory pre-
clinical study similar to guidelines used in patient trials.
One important aspect that differs between the dis-
eases studied is the choice of the animal model and
of the efficacy readouts that reflect human outcome
measures for that condition. In the case of neuromus-
cular diseases, histological and biochemical data serve
to quantify changes at the molecular level and can be
determined with more precision and with larger sam-
ple sizes. Functional assays, including the assessment
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Table 1
Suggested steps to consider in the planning and reporting of a confirmatory preclinical study
Study phase Actions
Study design Identify appropriate outcome measures
Determine appropriate sample size required
Determine inclusion and exclusion criteria
Determine appropriate species, sex, age and duration of intervention
Animal handling Include placebo and wild type controls
Determine litter size
Randomize animals in groups
Results collection Plan blinded experiment conduct and evaluation of results
Perform experiments at the same time of the day preferably by the same person
Use standard protocols to quantify outcome measures
Replicate experiments
Interpretation Determine procedures for dealing with dropouts or deaths
Determine significance
Determine dose-response results
Use appropriate statistical analysis
Reporting Report genetic background, age, sex, number of animals
Report negative results
Report husbandry conditions and diet
Report raw data
of locomotion, muscle force or overall health, deliver
information that may be of importance in the evaluation
of the benefit in clinical trials and might be beyond any
real improvement of the disease condition. Therefore, a
balanced choice of in-vitro and in-vivo assays is recom-
mended in mouse models for neuromuscular diseases.
Beyond the choice of outcome measures, the need of
standardized protocols to assess them became evident
already some years ago. For some animal models, such
protocols are available [20, 21]. The use of standard
operating procedures (SOPs) offers the possibility of
evaluating variability and calculating the required sam-
ple size by power analysis for a specific assay, and to
determine the natural history and reference data for a
parameter in a given model.
In the example of the mdx mouse model for DMD,
the experimental use of the animal model underwent
a progressive increase over the years. A search in
PubMed simply using “mdx mouse”, reported a total of
2409 articles from 1984 (the date this model was first
described) up to October 2014; the number of publi-
cations steadily increased from 2000 to 2007 and then
stabilized at more than 100/year. In parallel, the focus
on standardization of experimental approaches started
in 2007 and was a dynamic step-wise process which
required some time to reach a consensus [5, 16]. Under
the assumption that less than half of the published arti-
cles deals with “therapeutics”, the full acceptance of
using SOPs for pre-clinical drug tests in such a large
community may require time and a clear communi-
cation on how improving standardization may help
translational activity.
Another issue that has to be considered, which is
not directly related to the animal model, is the fact
that most of the studies conducted face the need of
publication. Journal editors mainly require two main
things: a) novelty and b) impressive results. A novel
study, even when based on a strong rationale and an
important hypothesis will hardly be published when
negative results are obtained. Impressive confirmatory
results that lack novelty may encounter similar prob-
lems. Related to this aspect is the need (often required
by reviewers and editors) of having suggestive titles
even for proof-of-concept studies, with the idea that
this may attract more readers and citations compared
to a more neutral one. It is easy to conclude about
the immediate consequences of these aspects, espe-
cially for orphan diseases in which the unmet clinical
need and the expectation of a therapy are compelling.
A journal policy oriented toward the publication of
well conducted and well described studies, indepen-
dently of their negative or positive results, is already
implemented by journals like Plos One. The adoption
of this model by editors in the neuromuscular field
would undoubtedly help in progressing research and
in avoiding unnecessary efforts and investments.
THE ROLE OF THE RESEARCH
COMMUNITY AND STAKEHOLDERS IN
IMPROVING TRANSLATION
The responsibility to improve the predictive power
of preclinical experiments should not solely depend
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on the decision of single laboratories. It is a combined
effort of research community, funding organization
and journal editors that will lead to the desired change.
In 2011, a meeting in Washington D.C. to discuss
such responsibilities resulted in guidelines that will
be used by NIH in evaluating grants ([22], see also
http://grants.nih.gov/ grants/ guide/ notice-files/ NOT-
NS-11-023.html). The TREAT-NMD Advisory Com-
mittee for Therapeutics (TACT), set up by the
EU-funded Network TREAT-NMD as a tool to help
promising therapies to reach patients as quickly
as possible, provides guidance on advancing new
therapies for neuromuscular diseases and requires
the use of SOPs where applicable. Many companies
involved in the development of therapeutics for DMD
are aware of the need of proper standardization of
preclinical tests, and require SOP adherence when
collaborating with academia or CROs. Nature and
Science Translational Research published a checklist
for authors that includes reporting and statistical
guidelines that need to be followed in the submitted
manuscripts [23, 24]. Recently, a workshop was
organized by TREAT-NMD to provide a coordi-
nated response to the public consultation on the
draft guideline “Clinical investigation of medicinal
products for the treatment of DMD and BMD”
released by the European Medicine Agency (EMA)
in 2013. The workshop brought together academics,
patient representatives, industry representatives and
individual experts. Among the various points, the
draft guidelines of EMA pointed out that the proposed
mechanism of action of any new product should be
described and discussed in relation to possible testing
in available animal models, which were, however,
described as poor. One issue of the workshop focused
therefore on animal models and it was emphasized
how the effort of TREAT-NMD in implementing and
disseminating proper use of valuable animals models
by means of SOPs served to initiate the discussion
on quality and how transparency, blinding and power
calculation, along with a better distinction between
primary and secondary outcome measures, may
improve predictability of results [25].
As shown by these few examples, awareness on the
issue of study quality can be raised if journals, grant
funding organisations and regulatory agencies insist on
standards for preclinical studies. Pre-clinical research
may learn from what has been previously discussed
for clinical trials. For instance, the publication of the
consolidated standards for reporting trials (CONSORT
statement) in 2001 resulted in a strong improvement
as to how trials were reported in journals [26]. This
is also reflected by the position taken by the Inter-
national Committee of Medical Journal Editors, that
paved the way toward having transparent public reports
of clinical trials and their outcome [27, 28]. In 2004,
an editorial of this Committee underlined the risk of
bias when a selective publication policy is used. It
was emphasized that researchers and journal editors
are generally keen to publish trials that show either a
large effect of a new treatment (positive trials) or non-
inferiority results (equivalence of two approaches to
treatments) and that they are generally less interested in
publishing negative or inconclusive trials. The editorial
pushed for a transparent reporting of clinical trials, with
exact mentioning of existing evidences in the specific
field at the time of article submission to the associated
medical journals, in order to reduce the potential bias
from selective publication; and underlined that, rather
than a single trial, it is usually a body of evidence from
many studies that changes medical practice. Such an
effort is needed also for pre-clinical tests, especially
when the limited patient population requires a careful
selection of best candidates for human testing.
The issue of investing time and funding in defining
best practices and standard protocols for animal models
of diseases definitely deserves more attention. Specific
grants by funding agencies and international projects
should be dedicated to the characterization of mouse
and other animal models (see also [29]), their natural
histories and variability of analysis; and to workshops
aimed at finding consensus on animal-specific guide-
lines and protocols.
CONCLUSION
The development of therapeutic approaches for rare
neuromuscular diseases is an urgent medical need
coupled with expectations and hopes of an overall sig-
nificant group of patients. Therefore, the applicability
of preclinical findings to human trials is of particular
importance. Exploratory and proof-of-concept studies
where drugs are used to validate a pathology-related
pathway, are often translated too quickly into clini-
cal trials if results showed some evidence of beneficial
modulation of the diseases in the mouse. This makes
it difficult to prioritize candidates for clinical trials on
a limited patient population and increases the risk of
clinical failure for testing a drug which in fact has not
robust pre-clinical evidence. In addition, a drug fail-
ing a clinical test often leads to the conclusion that the
animal model is of limited usefulness because not rep-
resentative of the human disease. Rather, the in-depth
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knowledge of the model will help identifying potential
targetsandpredicting ifadrugmayworkinhumans,and
preclinical studies conducted with the appropriate rigor
will help understanding which signs or symptoms are
more likely to be improved in humans. The use of SOPs
for functional and biochemical assays and of common
guidelines in the conduct of preclinical confirmatory
studies is therefore the way to pursue and to improve to
obtain more comparable results between different lab-
oratories and a higher translational success.
The aim of this review was to try to reconcile dif-
ferent positions, and to fill the gap between scientific
community, clinical needs and editorial policy. This
may help to better harmonize the scientific progress
reached by basic science with the investments into
drug development and clinical studies and to possi-
bly improve the final common goal: a better therapy
for neuromuscular disorders.
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